771 related articles for article (PubMed ID: 37042255)
21. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
López-López JA; Sterne JAC; Thom HHZ; Higgins JPT; Hingorani AD; Okoli GN; Davies PA; Bodalia PN; Bryden PA; Welton NJ; Hollingworth W; Caldwell DM; Savović J; Dias S; Salisbury C; Eaton D; Stephens-Boal A; Sofat R
BMJ; 2017 Nov; 359():j5058. PubMed ID: 29183961
[No Abstract] [Full Text] [Related]
22. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
[TBL] [Abstract][Full Text] [Related]
23. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants.
Aggarwal R; Ruff CT; Virdone S; Perreault S; Kakkar AK; Palazzolo MG; Dorais M; Kayani G; Singer DE; Secemsky E; Piccini J; Tahir UA; Shen C; Yeh RW
Circulation; 2023 Sep; 148(12):936-946. PubMed ID: 37621213
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Goodman SG; Wojdyla DM; Piccini JP; White HD; Paolini JF; Nessel CC; Berkowitz SD; Mahaffey KW; Patel MR; Sherwood MW; Becker RC; Halperin JL; Hacke W; Singer DE; Hankey GJ; Breithardt G; Fox KA; Califf RM;
J Am Coll Cardiol; 2014 Mar; 63(9):891-900. PubMed ID: 24315894
[TBL] [Abstract][Full Text] [Related]
25. Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.
Law SWY; Lau WCY; Wong ICK; Lip GYH; Mok MT; Siu CW; Chan EW
J Am Coll Cardiol; 2018 Jul; 72(3):271-282. PubMed ID: 30012320
[TBL] [Abstract][Full Text] [Related]
26. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
[TBL] [Abstract][Full Text] [Related]
27. Bleeding Risk of Direct Oral Anticoagulants in Patients With Heart Failure And Atrial Fibrillation.
Jackevicius CA; Lu L; Ghaznavi Z; Warner AL
Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007230. PubMed ID: 33541109
[TBL] [Abstract][Full Text] [Related]
28. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
[TBL] [Abstract][Full Text] [Related]
31. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
32. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
Carnicelli AP; Hong H; Giugliano RP; Connolly SJ; Eikelboom J; Patel MR; Wallentin L; Morrow DA; Wojdyla D; Hua K; Hohnloser SH; Oldgren J; Ruff CT; Piccini JP; Lopes RD; Alexander JH; Granger CB;
Am Heart J; 2021 Mar; 233():48-58. PubMed ID: 33296688
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Wang Y; Li L; Wei Z; Lu S; Liu W; Zhang J; Feng J; Wang D
Medicines (Basel); 2023 Jan; 10(1):. PubMed ID: 36662497
[TBL] [Abstract][Full Text] [Related]
34. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Fox KA; Piccini JP; Wojdyla D; Becker RC; Halperin JL; Nessel CC; Paolini JF; Hankey GJ; Mahaffey KW; Patel MR; Singer DE; Califf RM
Eur Heart J; 2011 Oct; 32(19):2387-94. PubMed ID: 21873708
[TBL] [Abstract][Full Text] [Related]
35. New oral anticoagulants for atrial fibrillation: a review of clinical trials.
O'Dell KM; Igawa D; Hsin J
Clin Ther; 2012 Apr; 34(4):894-901. PubMed ID: 22417716
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.
Patel SM; Braunwald E; Steffel J; Boriani G; Palazzolo MG; Antman EM; Bohula EA; Carnicelli AP; Connolly SJ; Eikelboom JW; Gencer B; Granger CB; Morrow DA; Patel MR; Wallentin L; Ruff CT; Giugliano RP;
Circulation; 2024 Mar; 149(12):932-943. PubMed ID: 38264923
[TBL] [Abstract][Full Text] [Related]
37. Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Significant Tricuspid Regurgitation.
Yang Y; Kim M; Kim J; Cho MS; Lee S; Song JM; Kim DH
J Am Heart Assoc; 2024 Feb; 13(3):e032272. PubMed ID: 38293966
[TBL] [Abstract][Full Text] [Related]
38. An Evidence-Based Approach to Anticoagulation Therapy Comparing Direct Oral Anticoagulants and Vitamin K Antagonists in Patients With Atrial Fibrillation and Bioprosthetic Valves: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Suppah M; Kamal A; Saadoun R; Baradeiya AMA; Abraham B; Alsidawi S; Sorajja D; Fortuin FD; Arsanjani R
Am J Cardiol; 2023 Nov; 206():132-150. PubMed ID: 37703679
[TBL] [Abstract][Full Text] [Related]
39. Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation.
Mehta HB; An H; Ardeshirrouhanifard S; Raji MA; Alexander GC; Segal JB
Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008951. PubMed ID: 36453260
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
